NIBEC presents as a peptide based healthcare company to develop therapeutic peptide in the field of regenerative medicine (i.e., osteoporosis), anti-inflammatory/immune therapy (rheumatic arthritis (RA), inflammatory bowel disease (IBD), Non-alcoholic steatohepatitis (NASH)) and anti-cancer. The company has established peptide library through big data analysis including genomics, proteomics, and microbiomics. Overall, 500 peptide candidates for the treatment of disease were identified through peptide discovery (PEPscovery) technology. As for the targeted drug therapy, the company established targeted delivery platform called target oriented peptide therapeutics discovery (TOPscovery). Using this technology, intracellular disease target protein (i.e., protein kinase) can be controlled by the peptide. Peptide for osteoporosis treatment (NIPEP-OSS) under Phase I stage, the preclinical stage development of antiinflammatory/immunology and anticance peptide will be presented.